Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer

Published:2019-07-10 Issue:7 Volume:2 Page:e196879
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Yu Yunfang¹,Zeng Dongqiang²,Ou Qiyun¹,Liu Shengbo¹³,Li Anlin¹³,Chen Yongjian¹³,Lin Dagui¹³,Gao Quanlong¹³,Zhou Haiyu⁴,Liao Wangjun²,Yao Herui¹

Affiliation:

1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Oncology and Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

2. Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

3. Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang, China

4. Department of Thoracic Surgery, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Southern Medical University, South China University of Technology, Guangzhou, China

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

http:///jamanetworkopen/article-pdf/2/7/e196879/17695785/yu_2019_oi_190277.pdf

Reference55 articles.

1. Novel therapeutic targets on the horizon for lung cancer.;Tan;Lancet Oncol,2016

2. Lung cancer: current therapies and new targeted treatments.;Hirsch;Lancet,2017

3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.;Reck;N Engl J Med,2016

4. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057).;Horn;J Clin Oncol,2017

5. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.;Quoix;Lancet Oncol,2016

Cited by 188 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials;Clinical and Translational Oncology;2024-09-12

2. Review of immunotherapy in non-small cell lung cancer: mechanisms, clinical applications, and future prospects;Asia-Pacific Journal of Oncology;2024-09-11

3. Prognostic significance of immune-cell distribution and tumoral spread through air spaces – Multiplex spatial immunophenotyping analysis–;Heliyon;2024-09

4. Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2024-08-13

5. Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer;Med;2024-08